Immunome (IMNM) EBITDA Margin (2023 - 2025)

Immunome (IMNM) posted EBITDA Margin of 1157.61% for Q2 2025, up 24.12% on a QoQ basis from 1525.5% in Q1 2025, and up 53482.0% year-over-year from N/an in Q2 2024.

Immunome (IMNM) EBITDA Margin (2023 - 2025) Analysis & Trends

Immunome's EBITDA Margin history runs 3 years deep, the most recent figure standing at 1157.61% for Q2 2025.

  • Quarterly EBITDA Margin rose 53482.0% year-over-year to 1157.61% in Q2 2025, while the trailing twelve-month figure through Mar 2026 was 5947.9% (down 395359.0% YoY) and the FY2025 annual result came in at 3228.83%, up 15354.0% from the prior year.
  • EBITDA Margin was 1157.61% for Q2 2025 at Immunome, up from 1525.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 129.96% in Q3 2023 and bottomed at 12857.05% in Q1 2024.
  • A 3-year average of 2492.75% and a median of 1608.96% in 2025 frame the typical range for EBITDA Margin.
  • Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 1266792 bps — and 2025, when it surged 1133155 bps.
  • Immunome's EBITDA Margin stood at 2473.94% in 2023, then dropped by 22 bps to 3030.31% in 2024, then surged by 62 bps to 1157.61% in 2025.
  • Business Quant data shows IMNM's EBITDA Margin at 1157.61% in Q2 2025, 1525.5% in Q1 2025, and 3030.31% in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Immunome 2.49 Bn 1.91 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 -1,157.61%
Mar 31, 2025 -1,525.50%
Dec 31, 2024 -3,030.31%
Sep 30, 2024 -1,736.15%
Jun 30, 2024 -1,692.43%
Mar 31, 2024 -12,857.05%
Dec 31, 2023 -2,473.94%
Sep 30, 2023 -129.96%
Jun 30, 2023 -135.42%
Mar 31, 2023 -189.13%